欢迎来到《四川大学学报(医学版)》
冯小蓉, 尧捷, 吴涯, 等. 干细胞在特发性肺纤维化治疗中的研究与应用综述[J]. 四川大学学报(医学版), 2021, 52(3): 373-379. DOI: 10.12182/20210560304
引用本文: 冯小蓉, 尧捷, 吴涯, 等. 干细胞在特发性肺纤维化治疗中的研究与应用综述[J]. 四川大学学报(医学版), 2021, 52(3): 373-379. DOI: 10.12182/20210560304
FENG Xiao-rong, YAO Jie, WU Ya, et al. Research and Application of Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis: A Review[J]. Journal of Sichuan University (Medical Sciences), 2021, 52(3): 373-379. DOI: 10.12182/20210560304
Citation: FENG Xiao-rong, YAO Jie, WU Ya, et al. Research and Application of Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis: A Review[J]. Journal of Sichuan University (Medical Sciences), 2021, 52(3): 373-379. DOI: 10.12182/20210560304

干细胞在特发性肺纤维化治疗中的研究与应用综述

Research and Application of Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis: A Review

  • 摘要: 特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是一类呈急性或慢性进展的不可逆肺部疾病,最终会导致患者肺功能严重损害乃至死亡。目前,肺纤维化的发病机理尚不明确,无有效的治疗手段延缓病情进展。研究显示,干细胞作为机体的起源细胞,不仅参与机体各阶段的发育,在肺损伤修复方面也发挥重要作用。作为再生医学领域的明星细胞,干细胞移植为IPF的治疗提供了全新的思路。本文将结合现阶段国内外干细胞移植治疗IPF的最新动态,综述干细胞移植在IPF治疗中的机制研究与应用探索前沿。

     

    Abstract: Idiopathic pulmonary fibrosis (IPF) is a type of pulmonary disease that progresses acutely or slowly into irreversible pulmonary diseases, resulting in the end severe damages to patients' lung functions, as well as deaths. At present, the pathogenesis of pulmonary fibrosis is still not clear and there is no effective therapeutic measure available to control the progression of the disease. Research findings indicate that stem cells, being the origin of all cells of organisms, participate in the development of individuals at various stages and play an important role in repairing pulmonary tissue damage. Stem cells are attracting growing attention in the field of regenerative medicine, providing new ideas for treating IPF with transplanted stem cells. Herein, in order to better explore the potential applications of stem cell transplantation in treating IPF, we attempt to summarize preliminary studies of stem cell-mediated pulmonary remodeling after IPF, as well as cutting-edge clinical trials in stem cell-based IPF therapy.

     

© 2021 《四川大学学报(医学版)》编辑部 版权所有 cc

开放获取 本文遵循知识共享署名—非商业性使用4.0国际许可协议(CC BY-NC 4.0),允许第三方对本刊发表的论文自由共享(即在任何媒介以任何形式复制、发行原文)、演绎(即修改、转换或以原文为基础进行创作),必须给出适当的署名,提供指向本文许可协议的链接,同时标明是否对原文作了修改;不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问 https://creativecommons.org/licenses/by-nc/4.0

/

返回文章
返回